Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elite Pharmaceuticals ( (ELTP) ) has provided an announcement.
Elite Pharmaceuticals announced that it will release its second quarter financial results for the fiscal year 2026 on November 14, 2025, with a conference call scheduled for November 17, 2025, to discuss these results and provide a business update. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational progress, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (ELTP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.
Spark’s Take on ELTP Stock
According to Spark, TipRanks’ AI Analyst, ELTP is a Neutral.
The overall stock score is primarily impacted by financial performance and valuation concerns. While revenue growth is strong, profitability issues and cash flow inconsistencies pose significant risks. Technical analysis indicates mixed signals, with no clear trend, and valuation metrics are unattractive due to negative earnings and lack of dividends.
To see Spark’s full report on ELTP stock, click here.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and distributing niche generic products. Their product lines include immediate-release and controlled-release solid oral dose products, marketed under the Elite Laboratories label and through third-party licenses. The company operates a cGMP and DEA registered facility in Northvale, NJ.
Average Trading Volume: 1,225,456
Technical Sentiment Signal: Strong Buy
Current Market Cap: $672.6M
For a thorough assessment of ELTP stock, go to TipRanks’ Stock Analysis page.